India's Cipla to make and sell Eli Lilly's baricitinib to treat COVID-19

Baricitinib has been given restricted emergency use approval by India's drug regulator for use in combination with remdesivir for the treatment of hospitalised COVID-19 adult patients requiring supplemental oxygen, Cipla said in a filing to stock exchanges.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/33ujFzl
via IFTTT